Afatinib (BIBW 2992) is an orally active, irreversible EGFR and HER2 inhibitor (IC50s: 0.5 nM, 14 nM). It enhances adriamycin cytotoxicity in resistant lung cancer cells and reduces tumor growth in gastric cancer models. Used in NSCLC research. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.